Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia

Lancet Oncology

Volumn 1, Issue 2, 2000, Pages 101-106

  Wang, Zhen Yi ^a   Chen, Zhu ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; RETINOIC ACID; TUMOR PROTEIN;

ANIMAL; APOPTOSIS; BLEEDING DISORDER; CELL DIFFERENTIATION; DRUG EFFECT; HUMAN; METABOLISM; MINIMAL RESIDUAL DISEASE; PATHOPHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; HEMORRHAGIC DISORDERS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; TRETINOIN;

EID: 0034308663     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00017-6     Document Type: Review

References (33)

1. Huang ME, Ye YC, Chen SR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyclocytic leukemia. Chin Med J 1987; 100: 949-52.
2. Sun GL, Huang YG, Chang XF, et al. Chinese Cooperative Study Group on APL. Clinical study on all-trans retinoic acid in the treatment of 544 patients with acute promyelocytic leukemia. Chin J Hematol 1992; 13: 135-37.
3. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202-06.
4. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-28.
5. Asou N, Adachi K, Tamura J, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia; comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 1997; 40 suppl: S30-35.
6. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubin (AIDA) therapy. Gruppo Italiano-Malattie Emutologiche Maligne dell'Adulto and Associazoine Italiana di Ematologia ed Oncologia Pediatrica. Blood 1997; 90: 1014-21.
7. Fenaux P, Chastag C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-200.
8. Burnett AK, Grimwade, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131-43.
9. 3: an experience of 120 patients at a single institution. Int J Hematol 1999; 70: 248-60.
10. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996; 10: 825-28.
11. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
12. Wang ZY, Sun GL, Shen ZX, et al. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J 1999; 112: 963-67.
13. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90: 967-73.
14. Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia. Clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/PCR to predict relapse. Blood 1993; 82: 1264-69.
15. Estey E, Williams T. Liposomal tretinoin monotherapy induces and maintains clinical and molecular remission in patients with acute promyelocytic leukemia. 8th International Conference on Differentiation Therapy; 1999, Oct 3-6, Montreal, Canada, p 270.
16. Barbui T, Finazzi G, Falanga A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093-102.
17. Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999; 13: 1062-70.
18. Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998; 91: 2631-33.
19. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion protein. Proc Natl Acad Sci USA 1999; 96: 14807-12.
20. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemia by Al-1 therapy. Chin J Integrat Chin Trad Med West Med 1992; 12: 170-72.
21. Zhang P, Wang SY, Hu LH, et al. Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58-60.
22. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-61.
23. Zhang P, Wang SY, Hu LH, et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide: an analysis of 242 cases. Chin J Hematol 2000; 21: 67-70.
24. 3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
25. Niu C Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia. Blood 1999; 94: 3315-24.
26. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-48.
27. Soignet SL, Frankel S, Tallman M, et al. US Multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 1999; 94 (suppl 1): 698a (abstr 3084).
28. Camacho LH, Soignet SL, Heller G, et al. Leucocytosis and the 'retinoic acid syndrome' during induction treatment of acute promyelocytic leukemia with arsenic trioxide. Blood 1999; 94 (suppl 1):abstr 595.
29. Huang SL, Guo AX, Xiang Y, et al. Clinical study on he treatment of acute promyelocytic leukemia mainly with Composite Indigo Naturalis tablets. Chin J Hematol 1995; 16: 26-28.
30. Lu DP, Qiu JY, Jiang B, et al. Effective treatment of acute promyelocytic leukemia (APL) with tetra-arsenic tetrasulfide. Blood 1999; 94 (suppl 1): 698a (abstr 3085).
31. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.
32. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-70.
33. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-52.